P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

• John C. Byrd,
• Seema Ali Bhat,
• Farrukh Awan,
• Pratyush Giri,
• Sumita Ratnasingam,
• Roman Hájek,
• Dagmar Hess,
• Daniela Alves,
• Jan Maciej Zaucha,
• Annalise Shen,
• Elizabeth Bilotti,
• Jesse Mcgreivy,
• Wayne P. Rothbaum,
• Hanna Ciepluch

Affiliations

John C. Byrd

1 University of Cincinnati College of Medicine, Cincinnati, United States

Seema Ali Bhat

2 Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, Columbus, United States

Farrukh Awan

3 Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, United States

Pratyush Giri

4 Royal Adelaide Hospital, Adelaide, Australia

Sumita Ratnasingam

5 University Hospital Geelong (Barwon Health), Geelong, Australia

Roman Hájek

6 University Hospital Ostrava, Department of Hematooncology, Ostrava, Czech Republic

Dagmar Hess

7 Kantonsspital St. Gallen, St. Gallen, Switzerland

Daniela Alves

8 Centro Hospitalar Universitario de Lisboa Norte, Lisbon, Portugal

Jan Maciej Zaucha

9 Uniwersyteckie Centrum Kliniczne i Gdański Uniwersytet Medyczny, Klinika Hematologii i Transplantologii, Gdańsk, Poland

Annalise Shen

10 Kartos Therapeutics, Inc., Redwood City, CA, United States

Elizabeth Bilotti

10 Kartos Therapeutics, Inc., Redwood City, CA, United States

Jesse Mcgreivy

10 Kartos Therapeutics, Inc., Redwood City, CA, United States

Wayne P. Rothbaum

10 Kartos Therapeutics, Inc., Redwood City, CA, United States

Hanna Ciepluch

11 Copernicus Podmiot Leczniczy, Regional Oncology Center, Gdansk, Poland